Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.43 |
| ▸ | GBA1 | P04062 | 2/20 | 0.41 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.38 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.38 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 3/20 | 0.38 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.38 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | ARG1 | P05089 | 1/20 | 0.33 |
| ▸ | ARG2 | P78540 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23015324 | 0.85 | NCF1 (0.52) | NCF1CHRM5ADRA2CACHECXCR4 | |
| Hydrochloric Acid SCHEMBL29653378 | 0.83 | NCF1 (0.50) | NCF1CHRM5ADRA2CACHECXCR4 | |
| SCHEMBL14422030 | 0.83 | GBA1 (0.48) | GBA1GNAO1CHRM5ADRA2CCACNA2D1 | |
| SCHEMBL16303417 | 0.82 | GBA1 (0.50) | GBA1GNAO1CHRM5ADRA2CCACNA2D1 | |
| SCHEMBL22940151 | 0.82 | GBA1 (0.42) | GBA1GNAO1CHRM5ADRA2CCACNA2D1 | |
| SCHEMBL4031644 | 0.82 | GBA1 (0.42) | GBA1GNAO1CHRM5ADRA2CCACNA2D1 | |
| Hydrochloric Acid SCHEMBL5573130 | 0.81 | GBA1 (0.47) | GBA1GNAO1CHRM5ADRA2CCACNA2D1 | |
| SCHEMBL2570307 | 0.81 | GBA1 (0.47) | GBA1GNAO1CHRM5ADRA2CCACNA2D1 | |
| SCHEMBL12717723 | 0.80 | GNAO1 (0.47) | GBA1GNAO1CHRM5ADRA2CCACNA2D1 | |
| SCHEMBL134511 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3660069-B1 | FAST CURING EPOXY SYSTEMS | EVONIK OPERATIONS GMBH (DE) | 2024-01-03 | — | — | EP | claimed |
| CN-111234182-A | Fast curing epoxy system | 赢创运营有限公司 | 2020-06-05 | — | — | CN | claimed |
| US-20200172723-A1 | FAST-CURING EPOXY SYSTEMS | EVONIK OPERATIONS GMBH (DE) | 2020-06-04 | — | — | US | claimed |
| EP-3660069-A1 | FAST CURING EPOXY SYSTEMS | Evonik Operations GmbH (DE) | 2020-06-03 | — | — | EP | claimed |
| EP-3660069-B1 | FAST CURING EPOXY SYSTEMS | EVONIK OPERATIONS GMBH (DE) | 2024-01-03 | — | — | EP | disclosed |
| US-11254655-B2 | Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-02-22 | — | — | US | disclosed |
| US-20200283408-A1 | BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-09-10 | — | — | US | disclosed |
| US-10696656-B2 | Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-06-30 | — | — | US | disclosed |
| CN-111234182-A | Fast curing epoxy system | 赢创运营有限公司 | 2020-06-05 | — | — | CN | disclosed |
| US-20200172723-A1 | FAST-CURING EPOXY SYSTEMS | EVONIK OPERATIONS GMBH (DE) | 2020-06-04 | — | — | US | disclosed |
| EP-3660069-A1 | FAST CURING EPOXY SYSTEMS | Evonik Operations GmbH (DE) | 2020-06-03 | — | — | EP | disclosed |
| US-20190152951-A1 | BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-05-23 | — | — | US | disclosed |
| EP-1899324-B1 | Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE INC (US) | 2011-11-30 | — | — | EP | disclosed |
| US-20100249186-A1 | BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC | 2010-09-30 | — | — | US | disclosed |
| US-7759363-B2 | Benzimidazole-carboxamide compounds as 5-HT4, receptor agonists | THERAVANCE, INC. (US) | 2010-07-20 | — | — | US | disclosed |
| US-20090209582-A1 | Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-08-20 | — | — | US | disclosed |
| EP-1899324-A2 | BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | Theravance, Inc. (US) | 2008-03-19 | — | — | EP | disclosed |
| WO-2006127815-A2 | BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE, INC. (US) | 2006-11-30 | — | — | WO | disclosed |
| WO-2006127815-A2 | BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE, INC. (US) | 2006-11-30 | — | — | WO | disclosed |
| US-20060270652-A1 | Benzimidazole-carboxamide compounds as 5-HT4, receptor agonists | THERAVANCE, INC. | 2006-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200283408-A1 | BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | HTR4, HTR1A, HTR5A | NCF1 2327/4885GBA1 1393/4885GNAO1 399/4885 |
| US-20090209582-A1 | Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists | HTR4, HTR1A, HTR5A | NCF1 2194/4885GBA1 1105/4885GNAO1 464/4885 |
| US-20100249186-A1 | BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | HTR4, HTR1A, HTR5A | NCF1 2327/4885GBA1 1393/4885GNAO1 399/4885 |
| US-11254655-B2 | Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists | HTR4, HTR1A, HTR5A | NCF1 2327/4885GBA1 1393/4885GNAO1 399/4885 |
| US-10696656-B2 | Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists | HTR4, HTR1A, HTR5A | NCF1 2327/4885GBA1 1393/4885GNAO1 399/4885 |
| US-20060270652-A1 | Benzimidazole-carboxamide compounds as 5-HT4, receptor agonists | HTR4, HTR1A, HTR5A | NCF1 2406/4885GBA1 1524/4885GNAO1 412/4885 |
| US-20190152951-A1 | BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | HTR4, HTR1A, HTR5A | NCF1 2327/4885GBA1 1393/4885GNAO1 399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.